NCI Drug Dictionary
The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
recombinant cell-surface anchored sialidase DAS181
A recombinant sialidase fusion protein composed of a sialidase catalytic domain derived from Actinomyces viscosus, a constituent of the normal oral and gastrointestinal flora in humans, fused to a cell surface-anchoring domain, with potential anti-viral activity. Following administration by oral inhalation, DAS181 proteolytically removes sialic acid from the airway epithelium, which inhibits viral binding to and internalization by cells of the respiratory epithelium and prevents viral replication. The cell surface anchoring-domain of this agent may increase retention time and drug potency. Sialic acids in the respiratory tract are used by influenza and parainfluenza viruses to invade airway epithelial cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|Synonym:||273-666-neuraminidase [273-methionine] (actinomyces viscosus clone DAS181) fusion protein with 125-145-preproamphiregulin (human)|
|US brand name:||Fludase|
|Code names:||DAS181 |